pharmaphorum March 14, 2025
Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of “next-generation” drugs still in preclinical development.
The dramatic decision – which has been accompanied by the laying off of around half its workforce and a change in chief executive – comes after Sutro revealed positive results from a phase 2/3 trial of lead drug luveltamab tazevibulin (luvelta, also known as STRO-002) in platinum-resistant ovarian cancer in December.
Sutro said at the time that the 32% objective response rate (ORR) in the dose-finding stage of the REFRαME-O1 study had set up the second pivotal stage of the trial, and it was hoping to file for accelerated approval of the...